Sichuan Kelun Pharmaceutical Co., Ltd. Class A
002422
Rangering i aksjer
#2008
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and... Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Aksjekurs
$6.40
Markedsverdi
$10.19B
Endring (1 dag)
-0.77%
Endring (1 år)
27.14%
Land
CN
Handel Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Kategori
Healthcare
Inntekter for Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Inntekter i Jun 2026 TTM: $380.26M
Ifølge Sichuan Kelun Pharmaceutical Co., Ltd. Class A sine nyeste økonomiske rapporter er selskapets nåværende resultat $380.26M. I 2024 hadde selskapet et resultat på $587.11M, en økning sammenlignet med resultatet i 2023, som var $505.81M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Sichuan Kelun Pharmaceutical Co., Ltd. Class A fra 2007 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $380.26M | 10.67% |
| 2025 | $343.58M | -41.48% |
| 2024 | $587.11M | 16.07% |
| 2023 | $505.81M | 68.72% |
| 2022 | $299.79M | 61.80% |
| 2021 | $185.28M | 26.74% |
| 2020 | $146.19M | -18.97% |
| 2019 | $180.42M | -6.93% |
| 2018 | $193.85M | 10.51% |
| 2017 | $175.41M | 69.99% |
| 2016 | $103.19M | -1.58% |
| 2015 | $104.84M | -43.47% |
| 2014 | $185.46M | -12.29% |
| 2013 | $211.43M | 3.94% |
| 2012 | $203.43M | 14.70% |
| 2011 | $177.35M | 51.03% |
| 2010 | $117.43M | 53.61% |
| 2009 | $76.45M | 48.40% |
| 2008 | $51.51M | 46.84% |
| 2007 | $35.08M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | 1,287.20% |
US
|
|
| $-3.09B | -911.82% |
US
|
|
| $-4.02B | -1,156.18% |
AU
|
|
| $3.01B | 690.44% |
BE
|
|
| $1.95B | 412.98% |
NL
|
